首页 > 最新文献

Current Opinion in Supportive and Palliative Care最新文献

英文 中文
Supportive and palliative care for older adults with cancer. 老年癌症患者的支持性和姑息性护理。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/SPC.0000000000000633
Ines B Menjak, Schroder Sattar, Christopher Steer
{"title":"Supportive and palliative care for older adults with cancer.","authors":"Ines B Menjak, Schroder Sattar, Christopher Steer","doi":"10.1097/SPC.0000000000000633","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000633","url":null,"abstract":"","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9521704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual and gender diversity in cancer care and survivorship. 癌症治疗和生存中的性别多样性。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/SPC.0000000000000628
Christian Schulz-Quach, Margo Kennedy, Brendan Lyver

Purpose of the review: Sexual and gender diverse (SGD) cancer patients possess unique identities and needs that must be considered during their cancer care. This narrative review explores the current literature on sexual and gender diversity in cancer care and survivorship, in addition to providing recommendations encouraged by the current literature.

Recent findings: We performed a literature search for articles published in English between January 2021 and June 2022 in Medline ALL and Embase. Fifty-two studies were included in this review. The many identities encapsulated in 2SLGBTQIA+ (2 Spirited, Lesbian, Gay, Bisexual, Transgender, Queer, Intersexual, Asexual, Agender, Aromantic and all gender identities and sexual orientations that are not listed) communities each have their own unique backgrounds, needs and disparities in cancer care and survivorship. However, we also identified specific protective factors in the cancer experience of SGD patients such as reports of higher resiliency and stronger support networks. Much of the recent research features recommendations on improving cancer care by creating inclusive patient questionnaires, improving in-person and online resources, and educating healthcare providers and patient-facing staff on inclusive care.

Summary: SGD patients have their own specific challenges during and following their cancer care. As the research continues to grow, we gain a better understanding of the needs of these patients and future steps to take to improve SGD patients' cancer experience.

本综述的目的:性和性别多样性(SGD)癌症患者具有独特的身份和需求,必须在他们的癌症治疗中予以考虑。这篇叙述性综述探讨了目前关于癌症治疗和生存中性别和性别多样性的文献,并提供了当前文献所鼓励的建议。最近的发现:我们对Medline ALL和Embase在2021年1月至2022年6月期间发表的英文文章进行了文献检索。本综述纳入了52项研究。2SLGBTQIA+(意气风发、女同性恋、男同性恋、双性恋、变性人、酷儿、双性恋、无性恋、无性恋、浪漫以及所有未列出的性别身份和性取向)社区包含了许多身份,每个群体在癌症治疗和生存方面都有自己独特的背景、需求和差异。然而,我们也在SGD患者的癌症经历中发现了特定的保护因素,例如更高的弹性和更强的支持网络。最近的许多研究都提出了改善癌症治疗的建议,包括创建包容性的患者问卷,改善面对面和在线资源,以及对医疗保健提供者和面向患者的工作人员进行包容性治疗的教育。总结:SGD患者在癌症治疗期间和之后都有自己的特殊挑战。随着研究的继续发展,我们对这些患者的需求有了更好的了解,并在未来采取措施改善SGD患者的癌症体验。
{"title":"Sexual and gender diversity in cancer care and survivorship.","authors":"Christian Schulz-Quach,&nbsp;Margo Kennedy,&nbsp;Brendan Lyver","doi":"10.1097/SPC.0000000000000628","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000628","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Sexual and gender diverse (SGD) cancer patients possess unique identities and needs that must be considered during their cancer care. This narrative review explores the current literature on sexual and gender diversity in cancer care and survivorship, in addition to providing recommendations encouraged by the current literature.</p><p><strong>Recent findings: </strong>We performed a literature search for articles published in English between January 2021 and June 2022 in Medline ALL and Embase. Fifty-two studies were included in this review. The many identities encapsulated in 2SLGBTQIA+ (2 Spirited, Lesbian, Gay, Bisexual, Transgender, Queer, Intersexual, Asexual, Agender, Aromantic and all gender identities and sexual orientations that are not listed) communities each have their own unique backgrounds, needs and disparities in cancer care and survivorship. However, we also identified specific protective factors in the cancer experience of SGD patients such as reports of higher resiliency and stronger support networks. Much of the recent research features recommendations on improving cancer care by creating inclusive patient questionnaires, improving in-person and online resources, and educating healthcare providers and patient-facing staff on inclusive care.</p><p><strong>Summary: </strong>SGD patients have their own specific challenges during and following their cancer care. As the research continues to grow, we gain a better understanding of the needs of these patients and future steps to take to improve SGD patients' cancer experience.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9170296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Radiation therapy post radical prostatectomy: who, when and why? 根治性前列腺切除术后的放射治疗:谁,何时,为什么?
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/SPC.0000000000000627
Igor Latorzeff, Jennifer Le Guevelou, Paul Sargos

Purpose of review: During decades, adjuvant radiotherapy (ART) has been the standard of care after surgery, based on four randomized clinical trials (RCTs). As early salvage radiotherapy (SRT) recently challenged the ART paradigm, the optimal timing to initiate radiotherapy remains a matter of debate.

Recent findings: Three RCTs evaluated ART or SRT for postprostatectomy patients, with pathological risk factors (Gleason score > 8, pT3, positive margins). The ARTISTIC meta-analysis demonstrated similar 5-year biochemical recurrence-free survival for ART and SRT (89 vs. 88%). Lower rates of late genitourinary toxicity were demonstrated within the SRT arm, favouring early SRT in clinical practice.The addition of pelvic lymph node radiotherapy recently demonstrated an improvement in freedom from progression within the randomized RTOG 0534 trial, especially for patients with pretreatment prostate serum antigen (PSA) levels more than 0.35 ng/ml. The most appropriate androgen deprivation therapy duration remains a point of controversy.

Summary: The SRT approach can be favoured for the vast majority of patients, provided close monitoring of PSA and early treatment in the event of biochemical recurrence. Radiotherapy dose and volumes and ADT use might be correlated to SRT timing (early vs. late). Results from trials including genomic tests and metabolic imaging will probably help to refine these criteria.

回顾的目的:几十年来,基于四项随机临床试验(rct),辅助放疗(ART)一直是手术后的标准治疗。由于早期补救性放射治疗(SRT)最近挑战了抗逆转录病毒治疗范式,启动放射治疗的最佳时机仍然是一个有争议的问题。最近的发现:三个随机对照试验评估了ART或SRT治疗前列腺切除术后患者的病理危险因素(Gleason评分> 8,pT3,阳性边缘)。ART荟萃分析显示ART和SRT的5年生化无复发生存率相似(89% vs. 88%)。在SRT组中,晚期泌尿生殖系统毒性发生率较低,在临床实践中有利于早期SRT。在随机RTOG 0534试验中,骨盆淋巴结放疗的增加最近证明了自由进展的改善,特别是对于预处理前列腺血清抗原(PSA)水平超过0.35 ng/ml的患者。最合适的雄激素剥夺治疗持续时间仍然是一个有争议的问题。总结:SRT方法对绝大多数患者都是有利的,只要密切监测PSA并在生化复发时进行早期治疗。放疗剂量和体积以及ADT的使用可能与SRT的时间(早期和晚期)相关。包括基因组测试和代谢成像在内的试验结果可能有助于完善这些标准。
{"title":"Radiation therapy post radical prostatectomy: who, when and why?","authors":"Igor Latorzeff,&nbsp;Jennifer Le Guevelou,&nbsp;Paul Sargos","doi":"10.1097/SPC.0000000000000627","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000627","url":null,"abstract":"<p><strong>Purpose of review: </strong>During decades, adjuvant radiotherapy (ART) has been the standard of care after surgery, based on four randomized clinical trials (RCTs). As early salvage radiotherapy (SRT) recently challenged the ART paradigm, the optimal timing to initiate radiotherapy remains a matter of debate.</p><p><strong>Recent findings: </strong>Three RCTs evaluated ART or SRT for postprostatectomy patients, with pathological risk factors (Gleason score > 8, pT3, positive margins). The ARTISTIC meta-analysis demonstrated similar 5-year biochemical recurrence-free survival for ART and SRT (89 vs. 88%). Lower rates of late genitourinary toxicity were demonstrated within the SRT arm, favouring early SRT in clinical practice.The addition of pelvic lymph node radiotherapy recently demonstrated an improvement in freedom from progression within the randomized RTOG 0534 trial, especially for patients with pretreatment prostate serum antigen (PSA) levels more than 0.35 ng/ml. The most appropriate androgen deprivation therapy duration remains a point of controversy.</p><p><strong>Summary: </strong>The SRT approach can be favoured for the vast majority of patients, provided close monitoring of PSA and early treatment in the event of biochemical recurrence. Radiotherapy dose and volumes and ADT use might be correlated to SRT timing (early vs. late). Results from trials including genomic tests and metabolic imaging will probably help to refine these criteria.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9537099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Care needs of older patients with advanced cancer. 老年癌症晚期患者的护理需求。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2023-03-01 Epub Date: 2023-01-20 DOI: 10.1097/SPC.0000000000000636
Alex Molassiotis, Mian Wang

Purpose of review: This review summarized current research evidence examining care needs of older patients with advanced cancer in dealing with disease, treatment, and treatment-related side effects. It also identified gaps and directions for future research and practice.

Recent findings: Older patients with advanced cancer need support from health professionals, family, friends, and other social network members in the management of physical symptoms and functioning, psychosocial and spiritual care, information provision, and practical resolution of daily problems. As older patients are affected by aging-related factors, they usually have unique patterns of care needs compared with younger patients.

Summary: Currently, insufficient research evidence hinders a comprehensive understanding of care needs of older patients with advanced cancer, as well as potential influencing factors. Future efforts are needed to develop more sophisticated assessment methods and interventions to better understand and address care needs of older patients with advanced cancer.

综述目的:这篇综述总结了目前研究证据,检查了老年晚期癌症患者在处理疾病、治疗和治疗相关副作用方面的护理需求。它还确定了未来研究和实践的差距和方向。最近的研究结果:患有晚期癌症的老年患者需要卫生专业人员、家人、朋友和其他社会网络成员的支持,以管理身体症状和功能、心理和精神护理、信息提供和实际解决日常问题。由于老年患者受到衰老相关因素的影响,与年轻患者相比,他们通常有独特的护理需求模式。摘要:目前,研究证据不足,阻碍了对老年晚期癌症患者护理需求以及潜在影响因素的全面了解。未来需要努力开发更复杂的评估方法和干预措施,以更好地了解和解决患有晚期癌症的老年患者的护理需求。
{"title":"Care needs of older patients with advanced cancer.","authors":"Alex Molassiotis,&nbsp;Mian Wang","doi":"10.1097/SPC.0000000000000636","DOIUrl":"10.1097/SPC.0000000000000636","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review summarized current research evidence examining care needs of older patients with advanced cancer in dealing with disease, treatment, and treatment-related side effects. It also identified gaps and directions for future research and practice.</p><p><strong>Recent findings: </strong>Older patients with advanced cancer need support from health professionals, family, friends, and other social network members in the management of physical symptoms and functioning, psychosocial and spiritual care, information provision, and practical resolution of daily problems. As older patients are affected by aging-related factors, they usually have unique patterns of care needs compared with younger patients.</p><p><strong>Summary: </strong>Currently, insufficient research evidence hinders a comprehensive understanding of care needs of older patients with advanced cancer, as well as potential influencing factors. Future efforts are needed to develop more sophisticated assessment methods and interventions to better understand and address care needs of older patients with advanced cancer.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9521710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Immunotherapy for older patients with cancer. 癌症老年患者的免疫治疗。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2023-03-01 Epub Date: 2023-01-20 DOI: 10.1097/SPC.0000000000000637
Tatianny P Araujo Vargas, Abdullah Al-Humiqani, Danilo Giffoni De Mello Morais Mata, Ines B Menjak

Purpose of the review: The aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an abundance of evidence with recent updates including subgroups of older patients.

Recent findings: Studies with updated analyses and subgroups of older patients show that in general older patients benefit as well as younger patients and tolerate immunotherapy very well. However, in some instances of combination therapies which may expose patients to more toxicity, the benefits are reduced, and careful selection of older patients, including adjunctive assessments such as geriatric assessment, can help to identify the appropriate treatment for an individual patient.

Summary: Older adults remain underrepresented in clinical trials, including those involving immunotherapy. Therefore, efforts must be made to include more older patients in trials and to assess real-world evidence to inform decision-making.

综述的目的:本综述的目的是描述免疫检查点抑制剂在患有实体瘤的老年人中的临床应用和耐受性,其中有大量证据表明最近的更新,包括老年患者的亚组。最近的发现:对老年患者的最新分析和亚组的研究表明,一般来说,老年患者和年轻患者一样受益,对免疫疗法的耐受性很好。然而,在某些可能使患者暴露于更大毒性的联合疗法的情况下,益处会降低,仔细选择老年患者,包括辅助评估,如老年评估,可以帮助确定适合个体患者的治疗方法。摘要:老年人在临床试验中的代表性仍然不足,包括那些涉及免疫疗法的试验。因此,必须努力将更多的老年患者纳入试验,并评估现实世界的证据,为决策提供信息。
{"title":"Immunotherapy for older patients with cancer.","authors":"Tatianny P Araujo Vargas,&nbsp;Abdullah Al-Humiqani,&nbsp;Danilo Giffoni De Mello Morais Mata,&nbsp;Ines B Menjak","doi":"10.1097/SPC.0000000000000637","DOIUrl":"10.1097/SPC.0000000000000637","url":null,"abstract":"<p><strong>Purpose of the review: </strong>The aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an abundance of evidence with recent updates including subgroups of older patients.</p><p><strong>Recent findings: </strong>Studies with updated analyses and subgroups of older patients show that in general older patients benefit as well as younger patients and tolerate immunotherapy very well. However, in some instances of combination therapies which may expose patients to more toxicity, the benefits are reduced, and careful selection of older patients, including adjunctive assessments such as geriatric assessment, can help to identify the appropriate treatment for an individual patient.</p><p><strong>Summary: </strong>Older adults remain underrepresented in clinical trials, including those involving immunotherapy. Therefore, efforts must be made to include more older patients in trials and to assess real-world evidence to inform decision-making.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9521711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tests to uncover and assess breathlessness: a proposed framework. 揭示和评估呼吸困难的测试:一个拟议的框架。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-09-21 DOI: 10.1097/SPC.0000000000000617
Magnus Ekström

Purpose of review: Breathlessness is a common, distressing, and limiting symptom that many people avoid by reducing their activity. This review discusses exertional tests that can be used for uncovering and assessing breathlessness depending on the person's severity of illness, function, the setting, and aim of the assessment.

Recent findings: Standardized exertional tests are useful to uncover 'hidden' breathlessness earlier in people who may have adapted their physical activity to limit their breathing discomfort. In 'more fit' ambulatory people and outpatients, cardiopulmonary exercise testing is the gold standard for assessing symptom severity, underlying conditions, and mechanisms and treatment effects. Among field tests, the 6-min walk test is not useful for assessing breathlessness. Instead, the 3-min step test and walk test are validated for measuring breathlessness change in chronic obstructive pulmonary disease. In people with more severe illness (who are most often not breathless at rest), reported tests include upper limb exercise or counting numbers aloud, but a valid and useful test for this population is lacking.

Summary: A framework for selecting the most appropriate test to assess breathlessness validly is proposed, and research needs are identified.

综述目的:呼吸困难是一种常见的、令人痛苦的、限制性的症状,许多人通过减少活动来避免这种症状。这篇综述讨论了可用于揭示和评估呼吸困难的运动测试,这取决于患者的疾病严重程度、功能、评估环境和目的。最近的发现:标准化的运动测试有助于早期发现那些可能通过调整身体活动来限制呼吸不适的人的“隐性”呼吸困难。在“更健康”的门诊患者和门诊患者中,心肺运动测试是评估症状严重程度、潜在条件、机制和治疗效果的黄金标准。在实地测试中,6分钟步行测试对评估呼吸困难没有用处。相反,3分钟步进测试和步行测试被验证用于测量慢性阻塞性肺病患者的呼吸困难变化。在患有更严重疾病的人(他们在休息时通常不会呼吸困难)中,报告的测试包括上肢锻炼或大声数数,但缺乏对这一人群有效和有用的测试。摘要:提出了一个选择最合适的测试来有效评估呼吸困难的框架,并确定了研究需求。
{"title":"Tests to uncover and assess breathlessness: a proposed framework.","authors":"Magnus Ekström","doi":"10.1097/SPC.0000000000000617","DOIUrl":"10.1097/SPC.0000000000000617","url":null,"abstract":"<p><strong>Purpose of review: </strong>Breathlessness is a common, distressing, and limiting symptom that many people avoid by reducing their activity. This review discusses exertional tests that can be used for uncovering and assessing breathlessness depending on the person's severity of illness, function, the setting, and aim of the assessment.</p><p><strong>Recent findings: </strong>Standardized exertional tests are useful to uncover 'hidden' breathlessness earlier in people who may have adapted their physical activity to limit their breathing discomfort. In 'more fit' ambulatory people and outpatients, cardiopulmonary exercise testing is the gold standard for assessing symptom severity, underlying conditions, and mechanisms and treatment effects. Among field tests, the 6-min walk test is not useful for assessing breathlessness. Instead, the 3-min step test and walk test are validated for measuring breathlessness change in chronic obstructive pulmonary disease. In people with more severe illness (who are most often not breathless at rest), reported tests include upper limb exercise or counting numbers aloud, but a valid and useful test for this population is lacking.</p><p><strong>Summary: </strong>A framework for selecting the most appropriate test to assess breathlessness validly is proposed, and research needs are identified.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9184231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The burden and impact of chronic cough in severe disease. 重症慢性咳嗽的负担和影响。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.1097/SPC.0000000000000623
Össur Ingi Emilsson

Purpose of review: Chronic cough is common in severe diseases, such as COPD, interstitial lung disease, lung cancer and heart failure, and has a negative effect on quality of life. In spite of this, patients with cough sometimes feel their cough is neglected by healthcare workers. This review aims to briefly describe cough mechanisms, highlight the burden chronic cough can be for the individual, and the clinical impact of chronic cough.

Recent findings: Chronic cough is likely caused by different mechanisms in different diseases, which may have therapeutic implications. Chronic cough, in general, has a significant negative effect on quality of life, both with and without a severe comorbid disease. It can lead to social isolation, recurrent depressive episodes, lower work ability, and even conditions such as urinary incontinence. Cough may also be predictive of more frequent exacerbations among patients with COPD, and more rapid lung function decline in idiopathic pulmonary fibrosis. Cough is sometimes reported by patients to be underappreciated by healthcare.

Summary: Chronic cough has a significant negative impact on quality of life, irrespective of diagnosis. Some differences are seen between patients with and without severe disease. Healthcare workers need to pay specific attention to cough, especially patients with severe disease.

综述目的:慢性咳嗽常见于慢性阻塞性肺病、间质性肺疾病、肺癌和心力衰竭等严重疾病,对生活质量有负面影响。尽管如此,咳嗽患者有时会觉得他们的咳嗽被医护人员忽视。本文旨在简要介绍咳嗽的机制,强调慢性咳嗽对个体的负担,以及慢性咳嗽的临床影响。最近的研究发现:慢性咳嗽在不同疾病中可能有不同的机制,这可能具有治疗意义。一般来说,慢性咳嗽对生活质量有显著的负面影响,无论有无严重的合并症。它会导致社会孤立、反复发作的抑郁症、工作能力下降,甚至出现尿失禁等情况。咳嗽也可能预示着COPD患者更频繁的加重,以及特发性肺纤维化患者肺功能更快的下降。咳嗽有时报告患者被低估的医疗保健。总结:慢性咳嗽对生活质量有显著的负面影响,与诊断无关。在有和没有严重疾病的患者之间可以看到一些差异。医护人员需要特别注意咳嗽,特别是病情严重的患者。
{"title":"The burden and impact of chronic cough in severe disease.","authors":"Össur Ingi Emilsson","doi":"10.1097/SPC.0000000000000623","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000623","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic cough is common in severe diseases, such as COPD, interstitial lung disease, lung cancer and heart failure, and has a negative effect on quality of life. In spite of this, patients with cough sometimes feel their cough is neglected by healthcare workers. This review aims to briefly describe cough mechanisms, highlight the burden chronic cough can be for the individual, and the clinical impact of chronic cough.</p><p><strong>Recent findings: </strong>Chronic cough is likely caused by different mechanisms in different diseases, which may have therapeutic implications. Chronic cough, in general, has a significant negative effect on quality of life, both with and without a severe comorbid disease. It can lead to social isolation, recurrent depressive episodes, lower work ability, and even conditions such as urinary incontinence. Cough may also be predictive of more frequent exacerbations among patients with COPD, and more rapid lung function decline in idiopathic pulmonary fibrosis. Cough is sometimes reported by patients to be underappreciated by healthcare.</p><p><strong>Summary: </strong>Chronic cough has a significant negative impact on quality of life, irrespective of diagnosis. Some differences are seen between patients with and without severe disease. Healthcare workers need to pay specific attention to cough, especially patients with severe disease.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10627165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cardiometabolic side effects of androgen deprivation therapy in prostate cancer. 前列腺癌雄激素剥夺治疗的心脏代谢副作用。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.1097/SPC.0000000000000624
Marie-Lyssa Lafontaine, Andrea Kokorovic

Purpose of review: Androgen-deprivation therapy (ADT) is widely employed for treatment of advanced prostate cancer and it is considered the frontline therapy. However, the numerous adverse reactions associated with this treatment option are concerning and its potential association with cardiovascular diseases (CVD) should not be overlooked. In this review, we examine the literature on the cardiovascular side effects of ADT and the physiologic mechanisms underpinning the association with CVD. We will also specifically discuss the different findings regarding the interesting potential disparity in major cardiovascular events among GnRH agonist-treated patients compared with patients undergoing GnRH antagonist treatment.

Recent findings: Androgen-deprivation therapy increases the risk of developing CVD by altering the body composition, metabolism, vascular system, and cardiac physiology. GnRH agonists may pose a higher risk of cardiovascular mortality and morbidity than GnRH antagonists; however, this link remains to be determined. Furthermore, screening for cardiovascular risk factors before and during ADT treatment is a crucial step in preventing major adverse cardiac events in prostate cancer patients. Notably, preexisting CVD and comorbidities have been identified as major key elements predicting cardiovascular events. Early implementation of pharmacological and nonpharmacological treatment strategies is strongly suggested, and regular follow-up visits should be scheduled to continuously assess patients' cardiovascular risk under ADT.

Summary: ADT is a very powerful treatment option for advanced prostate cancer that improves survival outcomes but has the potential of considerably impacting patients' cardiovascular health. Medical optimization and close monitoring are crucial during treatment with ADT.

综述目的:雄激素剥夺疗法(ADT)被广泛应用于晚期前列腺癌的治疗,被认为是一线治疗方法。然而,与这种治疗方案相关的众多不良反应令人担忧,其与心血管疾病(CVD)的潜在关联不应被忽视。在这篇综述中,我们研究了有关ADT心血管副作用的文献以及ADT与CVD相关的生理机制。我们还将具体讨论GnRH激动剂治疗的患者与接受GnRH拮抗剂治疗的患者在主要心血管事件中的潜在差异的不同发现。最近的研究发现:雄激素剥夺治疗通过改变身体组成、代谢、血管系统和心脏生理来增加发生心血管疾病的风险。GnRH激动剂可能比GnRH拮抗剂具有更高的心血管死亡率和发病率风险;然而,这种联系仍有待确定。此外,在ADT治疗之前和期间筛查心血管危险因素是预防前列腺癌患者主要不良心脏事件的关键步骤。值得注意的是,已存在的CVD和合并症已被确定为预测心血管事件的主要关键因素。强烈建议早期实施药物和非药物治疗策略,并定期随访,持续评估患者在ADT下的心血管风险。摘要:ADT是晚期前列腺癌的一种非常有效的治疗选择,可改善生存结果,但有可能严重影响患者的心血管健康。在ADT治疗过程中,医疗优化和密切监测至关重要。
{"title":"Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.","authors":"Marie-Lyssa Lafontaine,&nbsp;Andrea Kokorovic","doi":"10.1097/SPC.0000000000000624","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000624","url":null,"abstract":"<p><strong>Purpose of review: </strong>Androgen-deprivation therapy (ADT) is widely employed for treatment of advanced prostate cancer and it is considered the frontline therapy. However, the numerous adverse reactions associated with this treatment option are concerning and its potential association with cardiovascular diseases (CVD) should not be overlooked. In this review, we examine the literature on the cardiovascular side effects of ADT and the physiologic mechanisms underpinning the association with CVD. We will also specifically discuss the different findings regarding the interesting potential disparity in major cardiovascular events among GnRH agonist-treated patients compared with patients undergoing GnRH antagonist treatment.</p><p><strong>Recent findings: </strong>Androgen-deprivation therapy increases the risk of developing CVD by altering the body composition, metabolism, vascular system, and cardiac physiology. GnRH agonists may pose a higher risk of cardiovascular mortality and morbidity than GnRH antagonists; however, this link remains to be determined. Furthermore, screening for cardiovascular risk factors before and during ADT treatment is a crucial step in preventing major adverse cardiac events in prostate cancer patients. Notably, preexisting CVD and comorbidities have been identified as major key elements predicting cardiovascular events. Early implementation of pharmacological and nonpharmacological treatment strategies is strongly suggested, and regular follow-up visits should be scheduled to continuously assess patients' cardiovascular risk under ADT.</p><p><strong>Summary: </strong>ADT is a very powerful treatment option for advanced prostate cancer that improves survival outcomes but has the potential of considerably impacting patients' cardiovascular health. Medical optimization and close monitoring are crucial during treatment with ADT.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10628878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Fertility preservation in uro-oncology. 泌尿肿瘤中的生育能力保存。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.1097/SPC.0000000000000621
Kieran J Moore, Carlos Delgado, Jesse Ory

Purpose of review: The purpose of this review is to highlight the demand for fertility preservation among cancer survivors and to draw attention to areas where healthcare workers need to improve. As technology advances, maximizing cryopreservation rates will be paramount to increase the ability individuals to conceive after cancer treatment.

Recent findings: Guidelines recommending discussion of fertility for those diagnosed with cancer have been shown to increase patient satisfaction and overall quality of life. Our review demonstrated that increasing counseling rates remains an ongoing challenge and should remain an area of improvement for all healthcare professionals working in the oncology field. Formal programs to improve patient and provider education and access to fertility preservation increase uptake of fertility preservation. For men, many options exist to cryopreserve sperm; a slight delay to achieve fertility preservation has not been shown to lead to worse outcomes. Cryopreservation strategies differ based on puberty status and remain an active area of clinical research.

Summary: Improving fertility outcomes for cancer survivors is possible with appropriate counseling techniques at the time of cancer diagnosis. Clinicians should challenge current barriers for patient access to fertility preservation surrounding cancer treatments.

综述的目的:本综述的目的是强调癌症幸存者对生育能力保存的需求,并提请注意卫生保健工作者需要改进的领域。随着技术的进步,最大限度地提高冷冻保存率对于提高个体在癌症治疗后怀孕的能力至关重要。最近的研究发现:指南建议对那些被诊断为癌症的人讨论生育问题,这已被证明可以提高病人的满意度和整体生活质量。我们的回顾表明,提高咨询率仍然是一个持续的挑战,应该继续是所有在肿瘤领域工作的医疗保健专业人员的改进领域。正式的方案,以提高患者和提供者的教育和获得生育能力保存增加吸收生育能力保存。对于男性来说,冷冻保存精子有很多选择;为了保持生育能力而进行的轻微延迟并没有显示会导致更糟糕的结果。冷冻保存策略因青春期状态而异,仍然是临床研究的活跃领域。摘要:在癌症诊断时采用适当的咨询技术,可以改善癌症幸存者的生育结果。临床医生应该挑战目前患者在癌症治疗中获得生育能力保护的障碍。
{"title":"Fertility preservation in uro-oncology.","authors":"Kieran J Moore,&nbsp;Carlos Delgado,&nbsp;Jesse Ory","doi":"10.1097/SPC.0000000000000621","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000621","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to highlight the demand for fertility preservation among cancer survivors and to draw attention to areas where healthcare workers need to improve. As technology advances, maximizing cryopreservation rates will be paramount to increase the ability individuals to conceive after cancer treatment.</p><p><strong>Recent findings: </strong>Guidelines recommending discussion of fertility for those diagnosed with cancer have been shown to increase patient satisfaction and overall quality of life. Our review demonstrated that increasing counseling rates remains an ongoing challenge and should remain an area of improvement for all healthcare professionals working in the oncology field. Formal programs to improve patient and provider education and access to fertility preservation increase uptake of fertility preservation. For men, many options exist to cryopreserve sperm; a slight delay to achieve fertility preservation has not been shown to lead to worse outcomes. Cryopreservation strategies differ based on puberty status and remain an active area of clinical research.</p><p><strong>Summary: </strong>Improving fertility outcomes for cancer survivors is possible with appropriate counseling techniques at the time of cancer diagnosis. Clinicians should challenge current barriers for patient access to fertility preservation surrounding cancer treatments.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10628880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-COVID-19 respiratory problems: burden and management. covid -19后呼吸道问题:负担和管理。
IF 2.1 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.1097/SPC.0000000000000619
Anna Kessler, Melissa Heightman, Ewen Brennan

Purpose of review: To describe the burden of post-COVID respiratory sequelae in posthospital and nonhospitalized COVID-19 survivors and to describe the priorities of clinical management.

Recent findings: Due to varying definitions of 'Long COVID' or 'Post-COVID', the prevalence of post-COVID sequelae or persisting symptoms is challenging to estimate but ranges from 2.3 to 51%. Risk factors for persistent post-COVID symptoms include age, female sex, deprivation, presence of comorbidities; and in posthospital COVID-19 survivors, the severity of acute infection. Common post-COVID respiratory symptoms include breathlessness, cough and chest pain and many individuals also experience exercise intolerance. The most common pulmonary function test abnormality is impaired diffusing capacity for carbon monoxide. In posthospital COVID-19 survivors, the prevalence of interstitial lung damage is 5-11%. Disordered breathing is common in all post-COVID patients and respiratory physiotherapy is helpful.

Summary: The vast numbers of COVID-19 infections globally implies that a large number of people will be affected by post-COVID sequelae even with conservative estimates. A significant number of people are affected for several months and up to years following acute infection. Post-COVID sequelae have a detrimental impact on quality of life and ability to work.

综述目的:了解2019冠状病毒病住院后和非住院幸存者的肺炎后呼吸后遗症负担情况,并探讨临床处理的重点。由于“长COVID”或“后COVID”的定义不同,COVID后后遗症或持续症状的患病率难以估计,但范围从2.3到51%。持续出现covid后症状的危险因素包括年龄、女性、贫困、存在合并症;在COVID-19住院后幸存者中,急性感染的严重程度。常见的新冠肺炎后呼吸道症状包括呼吸困难、咳嗽和胸痛,许多人还会出现运动不耐症。最常见的肺功能检查异常是一氧化碳扩散能力受损。在COVID-19住院后幸存者中,间质性肺损伤的发生率为5-11%。呼吸障碍在所有covid后患者中都很常见,呼吸物理治疗是有帮助的。总结:全球COVID-19感染人数众多,这意味着即使保守估计,仍有大量人口将受到COVID-19后后遗症的影响。相当多的人在急性感染后会受到几个月甚至几年的影响。covid后后遗症对生活质量和工作能力产生不利影响。
{"title":"Post-COVID-19 respiratory problems: burden and management.","authors":"Anna Kessler,&nbsp;Melissa Heightman,&nbsp;Ewen Brennan","doi":"10.1097/SPC.0000000000000619","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000619","url":null,"abstract":"<p><strong>Purpose of review: </strong>To describe the burden of post-COVID respiratory sequelae in posthospital and nonhospitalized COVID-19 survivors and to describe the priorities of clinical management.</p><p><strong>Recent findings: </strong>Due to varying definitions of 'Long COVID' or 'Post-COVID', the prevalence of post-COVID sequelae or persisting symptoms is challenging to estimate but ranges from 2.3 to 51%. Risk factors for persistent post-COVID symptoms include age, female sex, deprivation, presence of comorbidities; and in posthospital COVID-19 survivors, the severity of acute infection. Common post-COVID respiratory symptoms include breathlessness, cough and chest pain and many individuals also experience exercise intolerance. The most common pulmonary function test abnormality is impaired diffusing capacity for carbon monoxide. In posthospital COVID-19 survivors, the prevalence of interstitial lung damage is 5-11%. Disordered breathing is common in all post-COVID patients and respiratory physiotherapy is helpful.</p><p><strong>Summary: </strong>The vast numbers of COVID-19 infections globally implies that a large number of people will be affected by post-COVID sequelae even with conservative estimates. A significant number of people are affected for several months and up to years following acute infection. Post-COVID sequelae have a detrimental impact on quality of life and ability to work.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9184244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Current Opinion in Supportive and Palliative Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1